Alembic Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 533573 | NSE: APLLTD | Pharmaceuticals & Drugs | Small Cap

Alembic Pharma Share Price

1,103.20 18.95 1.75%
as on 09-Dec'24 16:59

DeciZen - make an informed investing decision on Alembic Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Alembic Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (CD):
32.95
Market Cap:
21,312.4 Cr.
52-wk low:
745
52-wk high:
1,296.2

Is Alembic Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Alembic Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Alembic Pharmaceuticals Ltd is a good quality company.

2. Is Alembic Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Alembic Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Alembic Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Alembic Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Alembic Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alembic Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 37.5%65.9%28.9%22.2%22.7%23.3%26.3%11.3%7.4%13.4%-
Value Creation
Index
1.83.91.10.60.70.71.0-0.2-0.50.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2,0563,1663,1353,1313,9354,6065,3935,3065,6536,2296,357
Sales YoY Gr.-54%-1%-0.1%25.7%17.1%17.1%-1.6%6.5%10.2%-
Adj EPS 14.83821.620.730.245.255.324.817.530.532.9
YoY Gr.-156.6%-43.1%-4.3%46.2%49.6%22.6%-55.2%-29.4%74.3%-
BVPS (₹) 46.984.7100.9117.8144.2170.8257.8266.5222.4245.1248.7
Adj Net
Profit
2797154073895698511,088487344600647
Cash Flow from Ops. 1729483293128124491,463552724803-
Debt/CF from Ops. 1.50.10.32.31.43.90.31.10.90.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%9.6%4.9%10.2%
Adj EPS 8.4%0.2%-18%74.3%
BVPS20.2%11.2%-1.7%10.2%
Share Price 9.9% 14.8% 10.9% 42.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
35.757.723.318.92328.726.39.57.213.113.3
Op. Profit
Mgn %
19.231.819.819.721.826.427.416.512.61515.8
Net Profit
Mgn %
13.622.613.112.714.717.919.69.26.19.610.2
Debt to
Equity
0.30.10.10.30.40.50.10.10.20.10
Working Cap
Days
18814615919418218618119218817497
Cash Conv.
Cycle
471626323869708810510246

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 13.30%

Sales growth has been subdued in last 3 years 4.92%

Net Profit has been subdued in last 3 years -18.00%

Sales growth is not so good in last 4 quarters at 6.08%

Latest Financials - Alembic Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 39.5 32.9
TTM Sales (₹ Cr.) 6,119 6,357
BVPS (₹.) 256 248.7
Reserves (₹ Cr.) 4,992 4,849
P/BV 4.24 4.36
PE 27.43 32.95
From the Market
52 Week Low / High (₹) 744.95 / 1296.15
All Time Low / High (₹) 34.00 / 1296.15
Market Cap (₹ Cr.) 21,312
Equity (₹ Cr.) 39.3
Face Value (₹) 2
Industry PE 44.5

Management X-Ray of Alembic Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Alembic Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales2,0563,1663,1353,1313,9354,6065,3935,3065,6536,229
Operating Expenses 1,6612,1612,5202,5163,0793,3923,9134,4324,9455,296
Manufacturing Costs307330354315358471491500561561
Material Costs6408248888869931,0391,2571,4461,7091,715
Employee Cost 3074735596237479061,0511,1331,1691,446
Other Costs 4085347206929819751,1141,3521,5061,574
Operating Profit 3951,0056156158561,2141,480874708933
Operating Profit Margin (%) 19.2%31.7%19.6%19.7%21.8%26.4%27.4%16.5%12.5%15.0%
Other Income 12933527148750329
Interest 4553182716185056
Depreciation 447283105115157183287275273
Exceptional Items 00000-440000
Profit Before Tax 3599365295417491,0001,368625355632
Tax 762161221201571992531041316
Profit After Tax 2837204074215938011,115521342616
PAT Margin (%) 13.8%22.7%13.0%13.4%15.1%17.4%20.7%9.8%6.1%9.9%
Adjusted EPS (₹)15.038.221.421.931.044.058.326.517.431.3
Dividend Payout Ratio (%)23%10%19%18%18%23%24%38%46%35%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 8851,5971,9022,2202,7193,2195,0675,2384,3704,818
Share Capital 38383838383839393939
Reserves 8471,5601,8652,1822,6813,1825,0285,1984,3314,779
Minority Interest0000-1-290000
Debt238114897089281,747200430636430
Long Term Debt1900500499887200000
Short Term Debt220114892084298610430636430
Trade Payables325566501759644626669706680736
Others Liabilities 4173493193766616281,026856378357
Total Liabilities 1,8652,6262,8114,0644,9526,1926,9617,2306,0646,341

Fixed Assets

Gross Block8611,0949501,2421,5232,1322,5452,8403,4683,875
Accumulated Depreciation3143861512493645817571,0421,0691,329
Net Fixed Assets5477087999931,1581,5521,7881,7982,3982,547
CWIP 83933961,0101,5511,8462,1832,304601524
Investments 253504249182361189693
Inventories3835706337349671,1881,4861,6101,4751,644
Trade Receivables3613503395264898653498071,0461,025
Cash Equivalents 2745116090206811066982127
Others Assets462400434668532643814523364382
Total Assets 1,8652,6262,8114,0644,9526,1926,9617,2306,0646,341

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 1729483293128124491,463552724803
PBT 3599365295417491,0001,368625355632
Adjustment 45708387118278102418488287
Changes in Working Capital -163139-166-181112-593238-367-58-96
Tax Paid -69-197-118-135-166-236-245-123-61-20
Cash Flow From Investing Activity -256-307-486-884-756-732-839-372-448-321
Capex -224-301-491-807-763-734-659-424-442-316
Net Investments -34-840-140-18648-7-8
Others 221-772237514
Cash Flow From Financing Activity 87-224-12950359155-597-217-262-438
Net Proceeds from Shares 000000734000
Net Proceeds from Borrowing -37-39-5500000000
Interest Paid -5-5-5-26-70-111-73-52-50-49
Dividend Paid -65-79-90-91-91-3260-275-197-157
Others 194-101-29120220592-1,259110-16-231
Net Cash Flow 3417-286-69115-12827-371445
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)36.2458.0223.2520.422426.9726.9110.117.1213.4
ROCE (%)37.5465.8628.8722.1522.6623.326.2811.257.4413.42
Asset Turnover Ratio1.281.411.150.910.870.830.820.750.851
PAT to CFO Conversion(x)0.611.320.810.741.370.561.311.062.121.3
Working Capital Days
Receivable Days56414050475441406061
Inventory Days6155708079859010610091
Payable Days175197219259258223188174148151

Alembic Pharmaceuticals Ltd Stock News

Alembic Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Alembic Pharma on 09-Dec-2024 16:59 is ₹1,103.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Dec-2024 16:59 the market cap of Alembic Pharma stood at ₹21,312.4.
The latest P/E ratio of Alembic Pharma as of 09-Dec-2024 16:59 is 27.43.
The latest P/B ratio of Alembic Pharma as of 09-Dec-2024 16:59 is 4.24.
The 52-week high of Alembic Pharma is ₹1,296.2 and the 52-week low is ₹745.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alembic Pharma is ₹6,119 ( Cr.) .

About Alembic Pharmaceuticals Ltd

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Awards and recognition

  • Forbes India Awards Mr Pranav Amin and Mr. Shaunak Amin as ‘NextGen Entrepreneurs of the Year’
  • 1st Runner up Position in Job Safety Analysis(JSA) - at CII Industrial Safety Summit 2016
  • The company’s Commitment towards Risk Management honoured at Gujarat Seminar and Conclave on Risk Management.
  • The company’s MDs honoured with 'Transformational Leader Award'
  • The company won 'HR event of the Year' and 'Outstanding contribution to the cause of Education' at the 'Gujarat Best Employer Brand Awards 2017'
  • The company won 'HR event of the Year' at the 'Gujarat Best Employer Brand Awards 2017'

Milestones

  • 1907: Started manufacturing tinctures and alcohol at Vadodara.
  • 1940: Started manufacturing cough syrup, vitamins, tonics and sulphur drugs.
  • 1961: Lal bahadur Shastri inaugurates the Penicillin plant.
  • 1967: Bulk manufacturing of Vitamin B12.
  • 1971: Erythromycin manufactured for the first time in India.
  • 1972: Althrocin a brand of Erythromycin launched.
  • 1997: Althrocin becomes top selling brand in India.
  • 1999: Alembic starts production of synthetic organic API.
  • 2000: Gets ISO 14000 certification for its facilities at Vadodara.
  • 2001: Starts manufacturing of Cephalosporin C.
  • 2007: Acquisition of non - oncology business of Dabur Pharma Ltd.
  • 2009: Addressed chronic therapies through multiple marketing divisions.
  • 2010: ANDA’s total filed 38. DMF total filed to 53 and get approval for 15.
  • 2011: Pharmaceutical Business demerged from Alembic - APL Listed.
  • 2012: Launched Dermatology division in domestic market with 8 products.
  • 2013: Launched first NDA with a partner. Commenced filing in EU, Australia and Brazil.
  • 2014: Formed a JV in Algeria- Alembic MAMI SPA to explore African market.
  • 2015: Launched Aripiprazole on Day-1. Established the U. S front-end, transition to own marketing in the U.S.
  • 2016: Formed JV 60:40 with Orbicular - “Aleor Dermaceuitical Limited” for developing Dermatology Products for international markets.
  • 2017: Shri. Vijay Rupani - Hon’ble Chief Minister of Gujarat, inaugurates the manufacturing facility for Oncology medicines (oral solids and liquid injectable vials).
  • 2017: Acquired Orit Laboratories LLC, USA.
  • 2018: FDA approved Aleor’s dermatology facility.
  • 2018: Highest ever investment commitment across four new manufacturing facilities.
  • 2019: FDA approves Oncology oral solid facility.
  • 2019: Formed a JV, to enter China.
  • 2020: US front-end achieved milestone of $ 250 Mn Sales in 2019-20.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.